Expert Opinion on Biological Therapy最新文献_第3页

Incidence of therapy switch in patients with moderate to severe palmoplantar psoriasis treated with anti-IL 17 and anti-IL 23 monoclonal antibodies: a retrospective observational study.

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2025-03-20 DOI: 10.1080/14712598.2025.2480756

Alessandra Michelucci, Flavia Manzo Margiotta, Filippo Fanetti, Brittany Chittano, Cristian Fidanzi, Salvatore Panduri, Riccardo Morganti, Marco Romanelli, Valentina Dini

{"title":"Incidence of therapy switch in patients with moderate to severe palmoplantar psoriasis treated with anti-IL 17 and anti-IL 23 monoclonal antibodies: a retrospective observational study.","authors":"Alessandra Michelucci, Flavia Manzo Margiotta, Filippo Fanetti, Brittany Chittano, Cristian Fidanzi, Salvatore Panduri, Riccardo Morganti, Marco Romanelli, Valentina Dini","doi":"10.1080/14712598.2025.2480756","DOIUrl":"https://doi.org/10.1080/14712598.2025.2480756","url":null,"abstract":"Background: The aim of this study is to confront the effectiveness of anti-IL 17 versus anti-IL 23 mAb in treating palmoplantar psoriasis by comparing the incidence of patients that required a therapy switch to another mAb class. Furthermore, we calculated the mean time intercurrent the beginning therapy with mAbs and the necessity to switch class due to ineffectiveness.Research design and methods: We enrolled 116 patients with moderate to severe palmoplantar psoriasis. Patients with the pustular variant were excluded from this study. We performed statistical analysis to calculate the incidence of therapy switch in anti-IL 17 and anti-IL 23 mAb therapies.Results: The results of both univariate and multivariate statistical analysis demonstrated that patients in therapy with anti-IL 23 mAb have a lower incidence of therapy switch compared to patients in therapy with anti-IL 17 drugs. The median switch time is 105 months. No other significant factors predictive of therapy switch were found.Conclusions: This real-life evidence confirms the reduced necessity of therapy switch in patients with palmoplantar psoriasis treated with anti-IL 23 antibodies, compared to those treated with IL 17 inhibitors.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"1-6"},"PeriodicalIF":3.6,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology. 精确治疗发作性偏头痛：由疾病生物学见解驱动的靶向治疗的不断发展的景观。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2025-03-01 Epub Date: 2025-02-02 DOI: 10.1080/14712598.2025.2456464

Robert Fleischmann, Sebastian Strauß, Uwe Reuter

{"title":"Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology.","authors":"Robert Fleischmann, Sebastian Strauß, Uwe Reuter","doi":"10.1080/14712598.2025.2456464","DOIUrl":"10.1080/14712598.2025.2456464","url":null,"abstract":"Introduction: Migraine is a disabling neurological disorder with a complex neurobiology. It appears as a cyclic disorder of sensory processing, affecting multiple systems beyond nociception. Overlapping mechanisms, including dysfunctional processing of sensory input from brain structures are involved in the generation of attacks.Areas covered: This review provides a comprehensive synthesis on migraine neurobiology, which was additionally informed by search of research databases (PubMed, ClinicalTrials.gov). Findings from the most recent literature are integrated in a pathophysiological framework. By combining mechanistic insights and clinical trial data, this review highlights the trajectory of precision medicine in migraine treatment, offering a perspective on the near future of targeted and individualized therapeutic strategies.Expert opinion: Recent advances in migraine neurobiology offer potential solutions to longstanding challenges. While targeted CGRP therapies have shown promise by addressing specific mechanisms, the pathophysiology of migraine suggests that combination therapies targeting multiple pathways could be beneficial in migraine prevention. The growing diversity of treatment options presents challenges in therapy selection, underscoring the need for predictive biomarkers. These innovations can optimize treatment strategies and improve patient outcomes. As the field progresses, personalized, multimodal approaches are poised to become the standard of care, significantly advancing precision medicine in this area.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"229-243"},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gene therapy for choroideremia: progress, potential and pitfalls.

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2025-03-01 Epub Date: 2025-02-23 DOI: 10.1080/14712598.2025.2459850

Maram E A Abdalla Elsayed, Jasmina Cehajic-Kepetanovic, Robert E MacLaren

引用次数: 0

Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges.

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2025-03-01 Epub Date: 2025-02-03 DOI: 10.1080/14712598.2025.2456485

Sowmya Cheruvu, David McMahon, James Larkin

{"title":"Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges.","authors":"Sowmya Cheruvu, David McMahon, James Larkin","doi":"10.1080/14712598.2025.2456485","DOIUrl":"10.1080/14712598.2025.2456485","url":null,"abstract":"Introduction: Melanoma has become the poster child for transformative outcomes in advanced malignancy from the use of immunotherapy over the last 10-15 years with median survival improving from ~ 1 to > 5 years. With the increasing repertoire of immune checkpoint inhibitors (ICI) and other novel immunotherapeutic approaches, integrating and sequencing treatments to create new paradigms has gained prominence, with focus on optimizing toxicity management and complex scenarios such as immunotherapy resistance, brain metastases, fertility, and duration of follow-up.Areas covered: In this review, we summarize the progress and emerging evidence in melanoma treatments to date and consider management and possible future directions to improve outcomes for above-mentioned specific patient cohorts.Expert opinion: Personalized care with integration of novel prognostic and predictive biomarkers is the way forward in tailoring not only patient selection and choice of therapy, but also duration of treatment and surveillance to allow for early recurrence detection and access to newer therapies such as tumor infiltrating lymphocytes (TIL) to maximize the curative fraction of melanoma patients. Further research is needed in optimizing ICI and other immunotherapy toxicity management, including reducing steroid exposure for better patient outcomes and preserving quality of life.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"245-256"},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma. 将美泊利珠单抗作为重度嗜酸性粒细胞性哮喘的附加维持疗法进行评估。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2025-03-01 Epub Date: 2025-01-30 DOI: 10.1080/14712598.2025.2457779

Zheng Zhu, Xiaoying Chen, Yiting Luo, Rui Feng, Zicong Zhou, Ruchong Chen

{"title":"An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma.","authors":"Zheng Zhu, Xiaoying Chen, Yiting Luo, Rui Feng, Zicong Zhou, Ruchong Chen","doi":"10.1080/14712598.2025.2457779","DOIUrl":"10.1080/14712598.2025.2457779","url":null,"abstract":"Introduction: Clinical experience with anti-interleukin (IL)-5 biologic therapies for severe asthma has been increasing, alongside deeper and broader research focusing on the role of IL-5 and the IL-5 targeted mepolizumab. This review aims to provide an update of the evidence on the role of IL-5 and mepolizumab, with discussions of the benefits of mepolizumab and its future potential, to promote the comprehension of the pathophysiology and therapeutic approaches to asthma.Areas covered: For this narrative review, we conducted a database search in PubMed and Embase using the keywords 'IL-5' and 'mepolizumab,' focusing on randomized controlled trials and real-world studies up to September 2024. An overview of the pathogenesis of severe asthma, new insights on the role of IL-5 and mepolizumab, and the evidence on the efficacy and safety of mepolizumab in the treatment of severe eosinophilic asthma is provided, and its benefits in clinical remission and future applications are also discussed.Expert opinion: Mepolizumab holds considerable promise in asthma treatment due to its mechanism of action and multiple potential benefits. In clinical practice, it may be worth considering the exploratory initiation of mepolizumab add-on treatment from the time of medium-dose inhaled glucocorticosteroid use.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"209-220"},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successes and failures: the latest advances in the clinical development of amyloid-β-targeting monoclonal antibodies for treating Alzheimer's disease.

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2025-03-01 Epub Date: 2025-02-07 DOI: 10.1080/14712598.2025.2463963

Francesco Panza, Vittorio Dibello, Rodolfo Sardone, Roberta Zupo, Fabio Castellana, Ivana Leccisotti, Maria Claudia Moretti, Mario Altamura, Antonello Bellomo, Antonio Daniele, Vincenzo Solfrizzi, Emanuela Resta, Madia Lozupone

{"title":"Successes and failures: the latest advances in the clinical development of amyloid-β-targeting monoclonal antibodies for treating Alzheimer's disease.","authors":"Francesco Panza, Vittorio Dibello, Rodolfo Sardone, Roberta Zupo, Fabio Castellana, Ivana Leccisotti, Maria Claudia Moretti, Mario Altamura, Antonello Bellomo, Antonio Daniele, Vincenzo Solfrizzi, Emanuela Resta, Madia Lozupone","doi":"10.1080/14712598.2025.2463963","DOIUrl":"10.1080/14712598.2025.2463963","url":null,"abstract":"Introduction: The amyloid cascade hypothesis postulated that the accumulation of amyloid-β (Aβ) was the first step of the Alzheimer's disease (AD) pathological process. Effective reduction of Aβ plaque load by numerous drug candidates, among which anti-Aβ monoclonal antibodies, has produced discussible clinical successes and several failures. It was questioned whether Aβ may be the principal AD pathogenic factor and a valid therapeutic target and if targeting Aβ different species could make the difference.Areas covered: This review article summarized successes and failures of anti-Aβ monoclonal antibody therapy for AD, delineating the latest advances for their clinical development also according to their target engagement and downstream biomarkers.Expert opinion: The preliminary success of the recent Phase III randomized clinical trials (RCTs) of lecanemab, donanemab, and remternetug, and lessons learned from the failure of previous anti-Aβ monoclonal antibodies RCTs, provided critical evidence to support the role of Aβ in AD pathogenesis. The loss of free Aβ instead of an Aβ toxicity may promote AD neuropathology. Cerebrospinal fluid analyses (i.e. increases in Aβ1-42) may indicate a potential benefit of anti-Aβ monoclonal antibodies in AD and downstream biomarkers should be considered for providing comprehension in cognitive and clinical efficacy of future AD RCTs.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"275-283"},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Literature review and expert opinion on diagnosis and current management of generalized pustular psoriasis.

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2025-03-01 Epub Date: 2025-02-13 DOI: 10.1080/14712598.2025.2464858

Angelo Valerio Marzano, Maria Concetta Fargnoli, Paolo Gisondi, Anna Balato, Luca Bianchi, Piergiacomo Calzavara-Pinton, Andrea Chiricozzi, Antonio Costanzo, Matteo Megna, Giuseppe Micali, Stefano Piaserico, Francesca Prignano

{"title":"Literature review and expert opinion on diagnosis and current management of generalized pustular psoriasis.","authors":"Angelo Valerio Marzano, Maria Concetta Fargnoli, Paolo Gisondi, Anna Balato, Luca Bianchi, Piergiacomo Calzavara-Pinton, Andrea Chiricozzi, Antonio Costanzo, Matteo Megna, Giuseppe Micali, Stefano Piaserico, Francesca Prignano","doi":"10.1080/14712598.2025.2464858","DOIUrl":"10.1080/14712598.2025.2464858","url":null,"abstract":"Introduction: Generalized pustular psoriasis (GPP) is a rare, chronic, systemic, autoinflammatory disease characterized by the eruption of sterile pustules, often accompanied by more general symptoms, such as fever, fatigue, and a burning sensation in the skin. GPP can be potentially life-threatening, if untreated, as it can lead to complications, such as sepsis and heart failure.Areas covered: In this literature review and expert opinion article, we provide an overview of the epidemiology, pathogenesis, clinical presentation, diagnosis, and treatment of GPP. Eleven dermatologists representing seven different Italian regions considered relevant evidence in the literature to discuss the current diagnosis and treatment of GPP. The expert panel of dermatologists identified several weaknesses in the current clinical management of GPP.Expert opinion: There is an inconsistent definition and classification of the disease across the literature, which can lead to misdiagnosis and delay in disease treatment. Furthermore, there are no international and standardized clinical guidelines on disease management, especially in Europe. There is a profound need for the development of novel therapeutic agents with sustained efficacy to decrease the impact of the comorbidities and mortality associated with GPP, prevent the onset of complications, and support the unmet needs of these patients.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"265-273"},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143381867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How should we approach salvage therapy in advanced renal cell carcinoma after first-line immunotherapy combinations?

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2025-03-01 Epub Date: 2025-02-03 DOI: 10.1080/14712598.2025.2459193

Paul Sackstein, Michael B Atkins

引用次数: 0

An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma.

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2025-03-01 Epub Date: 2025-02-16 DOI: 10.1080/14712598.2025.2465825

Zachary M Avigan, Mohammad A Rattu, Joshua Richter

{"title":"An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma.","authors":"Zachary M Avigan, Mohammad A Rattu, Joshua Richter","doi":"10.1080/14712598.2025.2465825","DOIUrl":"10.1080/14712598.2025.2465825","url":null,"abstract":"Introduction: Bispecific antibody therapies, primarily targeting B-cell maturation antigen (BCMA), have shown remarkable outcomes in the treatment of heavily pretreated patients with multiple myeloma (MM). However, there are no current head-to-head trials informing practice for selection or sequencing of optimal T cell redirection strategies in later lines of therapy. Linvoseltamab is a novel BCMA-targeted bispecific antibody that was recently evaluated in the phase 1/2 LINKER-MM1 trial and is currently pending formal regulatory approval.Areas covered: In this drug evaluation, we review efficacy and toxicity profiles of linvoseltamab in the context of currently approved bispecific antibody therapies for MM. Specifically, we highlight differences in dosing strategy, cytokine release syndrome (CRS) kinetics, and indirect efficacy comparisons between trials of linvoseltamab and other bispecific antibodies.Expert opinion: Linvoseltamab has a similar efficacy profile with favorable CRS incidence and time-to-onset compared to other approved bispecific antibodies. Pending final regulatory approval and labeling, further real-world analyses are needed to evaluate its final role in the evolving landscape of T cell redirection therapy for MM.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"221-228"},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Steps towards the clinical application of endometrial and menstrual fluid mesenchymal stem cells for the treatment of gynecological disorders.

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2025-03-01 Epub Date: 2025-02-19 DOI: 10.1080/14712598.2025.2465826

Alexander Sadiasa, Jerome A Werkmeister, Shanti Gurung, Caroline E Gargett

{"title":"Steps towards the clinical application of endometrial and menstrual fluid mesenchymal stem cells for the treatment of gynecological disorders.","authors":"Alexander Sadiasa, Jerome A Werkmeister, Shanti Gurung, Caroline E Gargett","doi":"10.1080/14712598.2025.2465826","DOIUrl":"10.1080/14712598.2025.2465826","url":null,"abstract":"Introduction: The human endometrium is a highly regenerative tissue that contains mesenchymal stem/stromal cells (MSCs). These MSCs are sourced via office-based biopsies and menstrual fluid, providing a less invasive and readily available option for cell-based therapies. This review provides an update on endometrial-derived MSCs as a treatment option for gynecological diseases.Areas covered: This narrative review covers the characterization and therapeutic mechanisms of endometrium biopsy-derived MSCs (eMSCs) and menstrual fluid-derived mesenchymal stromal cells (MenSCs), highlighting similarities and differences. It also covers studies of their application in preclinical animal models and in clinical trials as potential cell-based therapies for gynecological diseases.Expert opinion: eMSCs and MenSCs from a homologous tissue source have the potential to promote regenerative activity as a treatment for gynecological diseases. Both eMSCs and MenSCs demonstrate therapeutic benefits through their paracrine activity in tissue regeneration, immunomodulation, angiogenesis, and mitigating fibrosis. Further research is essential to establish standardized isolation and characterization protocols, particularly for heterogeneous MenSCs, and to fully understand their mechanisms of action. Implementing SUSD2 magnetic bead sorting for purifying eMSCs from endometrial tissues and menstrual fluid is crucial for their use in future cell-based therapies. Optimization of production, storage, and delivery methods will maximize their therapeutic effectiveness.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"285-307"},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143381892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0